Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
Delayed Quote. Delayed Euronext Paris - 02/24 11:39:32 am
91.57 EUR   -1.89%
02/24J&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
02/24LONZA : France's Sanofi to carve out active drug ingredients business
RE
02/24SANOFI : Disclosure of trading in own shares
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/18/2020 02/19/2020 02/20/2020 02/21/2020 02/24/2020 Date
93.71(c) 94(c) 93.5(c) 93.33(c) 91.57(c) Last
2 506 543 2 236 271 1 998 520 2 138 010 3 871 463 Volume
+1.52% +0.31% -0.53% -0.18% -1.89% Change
More quotes
Financials (EUR)
Sales 2020 37 708 M
EBIT 2020 10 242 M
Net income 2020 5 609 M
Debt 2020 14 942 M
Yield 2020 3,57%
Sales 2021 39 415 M
EBIT 2021 10 677 M
Net income 2021 6 499 M
Debt 2021 11 188 M
Yield 2021 3,75%
P/E ratio 2020 20,4x
P/E ratio 2021 17,8x
EV / Sales2020 3,44x
EV / Sales2021 3,20x
Capitalization 115 B
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies,... 
Sector
Pharmaceuticals
Calendar
04/24Earnings Release
More about the company
Surperformance© ratings of Sanofi
Trading Rating : Investor Rating :
More Ratings
Latest news on SANOFI
02/24J&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
02/24LONZA : France's Sanofi to carve out active drug ingredients business
RE
02/24SANOFI : Disclosure of trading in own shares
GL
02/24SANOFI : to Create Pharmaceutical Ingredients Leader With Eyes to Spinoff
DJ
02/24Sanofi to create new industry leading European company to provide active phar..
GL
02/24SANOFI : to create new industry leading European company to provide active pharm..
GL
02/24Board of directors meeting of Sanofi - Aventis Pakistan Limited
AQ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/20SANOFI : Africatech 2020 Challenges Ready
AQ
02/19SANOFI : HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus ..
AQ
02/19EUROPEAN PRESS ROUNDUP : Blackhall Studios Expands to U.K., Greek Gas Network At..
DJ
02/19NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/19INNOVATION : MHRA's speedy approval of high dose flu vaccine demonstrates flexib..
AQ
02/19NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/18NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
News in other languages on SANOFI
01:19aSANOFI : Coronavirus : Sanofi, J&J, Moderna et consorts en quête d'un vaccin
01:10aSTOCK MARKET PARIS : Cette fois, le coronavirus est pris au sérieux
02/24SANOFI : veut créer une entité dédiée aux principes actifs
02/24SANOFI : veut créer une entité dédiée aux principes actifs
02/24SANOFI : rachat de 295.900 actions la semaine dernière
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 01/20
Close to major technical levels
SELL
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
02/24J&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
02/24Grain Futures Fall as Coronavirus Spreads
DJ
02/24NOVARTIS : FDA, EMA Accept Filings for Ofatumumab in Relapsing Multiple Sclerosi..
DJ
02/24DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/24ALLERGAN : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 102,14  €
Last Close Price 91,57  €
Spread / Highest target 24,5%
Spread / Average Target 11,5%
Spread / Lowest Target -7,17%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Chief Medical & Digital Officer
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI2.18%124 620
JOHNSON & JOHNSON2.78%395 024
ROCHE HOLDING AG10.13%300 195
NOVARTIS2.72%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.83%197 679